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Introduction
Type III hyperlipoproteinemia (type III HLP)' is a genetic disorder of lipid metabolism in humans that predisposes affected subjects to premature development of atherosclerosis (1) . Affected subjects demonstrate both hypercholesterolemia and hypertriglyceridemia, owing to accumulation in the plasma of abnormal lipoproteins: ,3-very low density lipoproteins ((-VLDL), which are remnants of both intestinal chylomicrons and hepatic VLDL. Type III HLP can be caused either by the expression of any of several receptor binding-defective variants of apo E ( 1, 2) or by apo E deficiency (3, 4) . Apo E normally functions as a ligand for remnant uptake by lipoprotein receptors (5) . In type III HLP, abnormal apo E causes impaired receptor-mediated lipoprotein catabolism that results in f,-VLDL accumulation (1) .
Most subjects with type III HLP are homozygous for apo E2(Cys-158), one of the three major polymorphic isoforms of apo E (1) . Several rare variants of apo E that are associated with type III HLP have also been described (2) . In most of these latter instances, heterozygosity for the rare variant apo E is sufficient for expression oftype III HLP, without the need for exacerbating factors usually required for type III HLP expression in apo E2(Cys-158 ) homozygotes ( 1, 2). One ofthese rare apo E variants, apo E(Arg-l 12, Cys-142), has been described in a family in which type III HLP occurs in four generations (6, 7) . All seven affected family members are heterozygous for apo E(Arg-112, Cys-142) (7); thus, the phenotype is transmitted as a dominant characteristic. In an attempt to explain the reason(s) for the dominant inheritance of type III HLP in apo E(Arg-l 12, Cys-142) subjects, Horie et al. studied some properties ofthis apo E variant that had been produced in bacteria by recombinant DNA techniques (8) . It was suggested that two properties ofapo E(Arg-l 12, Cys-142), in addition to its receptor binding defect, specifically contributed to dominant inheritance of type III HLP: its tendency to associate preferentially with triglyceride-rich lipoproteins, and its reduced heparin binding affinity. Both ofthese properties could lead to selective accumulation of the dysfunctional apo E in ,B-VLDL and, in turn, to dominant inheritance. Indeed, apo E(Arg-l 12, Cys-142) was shown to predominate over normal apo E3 by a 3:1 ratio in the f,-VLDL of an affected subject (8) .
Although studies of type III HLP have been insightful, an animal model of the disorder would be useful. Therefore, we created transgenic mice expressing the human apo E variant, apo E(Arg-l 12, Cys-142). The rationale for selecting this particular variant was twofold: First, since the transgenic apo E would be expressed on a background ofendogenous mouse apo E, the likelihood ofobtaining a type III HLP phenotype in mice would be greater with a variant known to yield type III HLP in humans coexpressing normal apo E3. Second, the apo E(Arg-112, Cys-142) variant is more like mouse apo E in that it contains arginine at the polymorphic site, residue 1 12 (mouse apo E contains arginine at the equivalent position, residue 104). The presence of arginine at this position confers upon human apo E a preference for association with triglyceride-rich lipoproteins (9, 10) .
Mouse models oflipoprotein metabolism, using both transgenic and gene targeting methodologies, are yielding important new information. In particular, the recent creation of transgenic mice overexpressing rat apo E ( 1 1, 12) and of null apo E mice by gene targeting ( 13, 14) has suggested the critical importance of apo E in lipoprotein metabolism in mice. While transgenic mice overexpressing rat apo E demonstrate reduced VLDL levels, the null apo E mice develop severe hypercholesterolemia and premature atherosclerosis, both on normal chow diets. Several of the characteristics of null apo E mice mimic human apo E deficiency and therefore these mice seem to be a reasonable model of that disorder. Likewise, in this report we demonstrate that mice expressing high levels of apo E(Arg-112, Cys-142) spontaneously develop hyperlipidemia and accumulate the abnormal lipoproteins, #l-VLDL, the hallmark characteristic of the disorder in humans.
Methods
DNA constructs. Two apo E(Arg-l 12, Cys-142) constructs were prepared for microinjection into mouse embryos. One contained a 3.8-kb SphI-BamHI fragment from the human apo E/CI/CI'/CII gene locus that directs high levels ofliver expression ofapo E and apo CI in transgenic mice ( 15, 16) . This element, provided by Dr. S. Simonet and Dr. J. Taylor, was ligated 5' to the parent HEGI apo E gene construct ( 17) . The second construct contained 5 kb of the 5' flanking region of the human apo A-I gene fused to exon one of the human apo E gene. This construct, provided by Dr. E. Spangler and Dr. E. Rubin, also directs high-level liver expression of apo E (Spangler, E., J. Verstuyft, and E. Rubin, manuscript submitted for publication). Into these two constructs were introduced the appropriate mutations, as previously described for a different vector (8) , yielding the vectors termed pHEGILE142 and pAIE 142, respectively.
Preparation oftransgenic mice. Transgenic mice were prepared by DNX Corp. (Princeton, NJ) commercial transgenic services by microinjection of either ofthe above constructs into C57BL/6 x SJL F2 hybrid embryos. At 4-5 wk ofage, the resulting mice were weaned and shipped to San Francisco, where they were maintained on a normal chow diet. Analysis for presence of the transgene was performed by Southern blotting of 10 jg of tail DNA using a human apo E cDNA probe ( 18) and by immunoblotting of I ul of plasma using a humanspecific anti-apo E polyclonal antisera ( 17, 19) . For pHEGlLE 142, 2 of 21 animals were positive; for pAIE142, 6 of 56 were positive. The transgene copy number was estimated by densitometric comparison with Southern blot of an equivalent amount of DNA from HepG2 cells. Human apo E plasma concentrations were determined by a radioimmunoassay specific for human apo E (10) .
Preparation oftotal RNA and ribonuclease protection assay. Total cellular RNA was isolated and analyzed as described by Simonet et ( 16, 19) . The gels were either dried for lipid staining with Fat Red 7B or blotted onto nitrocellulose and incubated consecutively with two antisera, one for detection ofhuman apo E (8) and the other for mouse apo E (20) . The human-specific antiserum against apo E showed very little crossreactivity with mouse apo E. In dilution assays using this antiserum, mouse apo E had a reaction intensity 20-fold lower than that of human apo E.2 For detection of mouse apo E, a rat-specific anti-apo E antiserum (20) was used that recognized mouse apo E but did not crossreact with human apo E.
Ultracentrifugation was performed on either plasma or pooled Superose 6 fractions at d = 1.006 g/ml in a model TL-100 tabletop centrifuge (Beckman Instruments, Inc., Fullerton, CA) for 2.5 h , 100,000 rpm at 10'C. The resulting 200 Ml d < 1.006 g/ml top fraction was either analyzed by agarose electrophoresis or delipidated by incubation in sample application buffer, and then electrophoresed at 80 V overnight on 5-20% SDS-polyacrylamide gradient gels. Gels were either stained with Coomassie brilliant blue R250 or transferred to nitrocellulose for immunoblotting.
Cholesterol and triglycerides were measured on a 50-Ml plasma sample ora I 00-Mul sample ofeach 500-Ml Superose 6 fraction by a colorimetric method (8) , adapted for use with a microplate reader. Cholesteryl ester contents of VLDL and fl-VLDL fractions were determined by difference after measurement of total cholesterol by an enzymatic method (Boehringer Mannheim Corp., Indianapolis, IN) and of free cholesterol with a kit (Free Cholesterol C; Wako, Osaka, Japan).
In vivo metabolism studies. Lipoproteins of d < 1.006 g/ml were obtained from 100 Ml of transgenic mouse plasma or 2 ml of pooled nontransgenic mouse plasma and iodinated by the method of Bilheimer et al. (21 ) . Specific activities ranged from 200 to 400 cpm/ng. 5 gg ofVLDL protein in 100 gl ofsaline was injected into the tail vein of normal mice. At each ofthree time points after injection (i.e., 5, 10, or 15 min) three to six mice were killed, blood was collected via heart puncture, and the liver was removed. Radioactivity of portions of plasma and liver was determined in a y counter and normalized to total plasma volume (defined as 3.5% of body weight) or total liver weight (22) .
Results
Eight founder mice expressing the apo E(Arg-l 12, Cys-142) variant were identified (Table I) . Although the transgene copy number varied only about sixfold, plasma levels ofapo E(Arg-112, Cys-142) varied 100-fold, from about halfthe endogenous mouse apo E level to a 50-fold excess. In female founders on a normal chow diet there was a strong direct correlation between the plasma levels of the human apo E and plasma cholesterol (linear regression analysis, r = 0.96) and a weaker correlation between apo E and plasma triglycerides (r = 0.80).
Liver-specific expression of the two constructs was verified by RNAse protection assays. Several tissues from mice expressing either pHEGlLE142 or pAIE142 were examined. As shown in Fig. 1 ides for the five nontransgenic littermates (three males, two females). The Superose 6 profiles of two of these transgenic offspring yielded cholesterol distributions similar to that ofthe founder, except that HDL cholesterol was reduced 35 and 20%, respectively, compared with nontransgenic littermates (data not shown).
In contrast to the above results, plasma from lines expressing lower levels ofthe variant apo E (2.5 or 21 mg/dl) demonstrated a lipoprotein profile that was more like that of nontransgenic mice (Fig. 2 B) . In Superose 6 fractions representing the major lipoprotein classes (as described in Methods) were pooled, concentrated, and subjected to agarose electrophoresis (Fig. 3) . The nontransgenic sample showed typical pre-3-migrating VLDL (Fig.  3, lane 1) and a slightly slower migrating remnant or IDL species (Fig. 3, lane 2) . Likewise, the VLDL fraction from the intermediate expresser was pre-#3-migrating (Fig. 3, lane 3) . In contrast, the comparable VLDL fraction from the transgenic animal expressing high levels of apo E(Arg-1 12, Cys-142) had a broad band extending well into the (3-migrating position (Fig.   3 , lane 5; compare its migration with IDL, lanes 2, 4, and 6).
To demonstrate that the (3-migrating lipoproteins from the Superose 6 chromatography were indeed ,B-VLDL (i.e., had a density < 1.006 g/ml), both the Superose 6 VLDL fraction and a whole plasma sample of the line 1 mouse were ultracentrifuged and the d < 1.006 g/ml top fractions were analyzed by agarose electrophoresis. This analysis showed that d < 1.006 g/ ml lipoproteins from either plasma or Superose 6 chromatography were 3-migrating, confirming their identification as (3-VLDL.
Apo E distribution among plasma lipoproteins was analyzed for both a high-expressing line (Fig. 4) (Table II) . The apolipoprotein content of these lipoproteins was revdaled by SDS-PAGE (Fig. 5) . As expected, transgenic d < 1.006 g/ml lipoproteins Agarose gel electrophoresis of pooled Superose 6 fractions was performed as described in Methods. Blotted gels of 100l-l plasma samples from either a line I mouse (A) or a line 2 mouse (B) were incubated first with the human-specific anti-apo E antiserum (left panels), and then stripped with a detergent solution and incubated with the rat-specific anti-apo E antiserum (right panels). In each instance, had human apo E associated with them, while nontransgenic VLDL did not. Densitometric scanning of the Coomassiestained gel indicated that in line 1 f3-VLDL (Fig. 5, lane 3) , the ratio of apo E(Arg-1 12, Cys-142) to mouse apo E was 7:1, while this ratio was only 2:1 in line 2 pre-f3-VLDL (Fig. 5, lane   4 ). This result and the lipoprotein distribution results of Fig. 4 suggest the possibility that a particular threshold ratio ofdefective to normal apo E may be required before f3-VLDL will accumulate in plasma. The d < 1.006 g/ml lipoproteins from both transgenics and nontransgenics had no apo A-I but appeared to have all the apo C's (data not shown). Because (23 ), while the liver makes only apo B 100. In rodents such as mice, however, the liver produces apo B48-containing lipoproteins in addition to apo B100-containing lipoproteins (24) , making the contribution of intestinal lipoproteins more difficult to assess. Nevertheless, the increased apo B48:apo B100 ratio in the apo E(Arg-l 12, Cys-142) high expressers suggests that there is accumulation ofapo B48-containing lipoproteins, similar to what occurs in humans with type III HLP. The lipid content of the d < 1.006 g/ml lipoproteins was also investigated (Table II) . In spite of the markedly elevated triglycerides, the cholesterol/triglyceride ratio in transgenic mouse ,B-VLDL was more than doubled compared with that of normal or of line 2 pre-f3-VLDL. However, the cholesterol enrichment ofthe transgenic mouse ,B-VLDL was less than that of ,B-VLDL from human subjects expressing the apo E(Arg-l 12, Cys-142) variant (Table II) . Both line 2 pre-f3-VLDL and line 1 ,B-VLDL had a higher percentage of total cholesterol as cholesteryl esters than did normal mouse VLDL, with more cholesteryl ester enrichment occurring in transgenic mouse (3-VLDL. However, the cholesteryl ester content was still lower than that of ,B-VLDL from the human subjects (Table II) .
A functional defect of the transgenic mouse ,B-VLDL was shown in plasma clearance experiments of injected, radiolabeled d < 1.006 g/ml lipoproteins (Fig. 6 ). Normal nontransgenic mouse VLDL was removed from the plasma of normal mice more rapidly than transgenic mouse f,-VLDL (66 vs. 36% of the injected dose at 15 min, P < 0.001 ). Accordingly, liver uptake of nontransgenic VLDL was more than that of transgenic f3-VLDL (42 vs. 18% of injected dose at 15 min, P < 0.001 ). These results directly demonstrate the impaired catabolism of mouse lipoproteins carrying the human apo E(Arg-1 12, Cys-142) variant. Table I ) expressing high levels of apo E(Arg- 1 of their cholesterol in HDL rather than in the apo B-containing lipoproteins VLDL, IDL, and LDL (25) . The severity of the hyperlipidemia in the transgenic mice, especially the hypercholesterolemia, appears to depend on the amount ofthe apo E variant expressed. Our data suggest that there is a threshold level ofapo E(Arg-l 12, Cys-142) required for accumulation of the abnormal f3-VLDL. Transgenic lines expressing levels of the apo E variant equal to or less than that of endogenous mouse apo E, which is 5-10 mg/dl in most strains (25) (Table  II) . A likely explanation for the lower level of cholesteryl ester enrichment in the f3-VLDL oftransgenic mice is the absence of cholesteryl ester transfer protein (CETP) activity in mouse plasma (26) . In humans, CETP facilitates the transfer of cholesteryl esters from HDL to VLDL and LDL (27) and may be the factor that primarily determines the cholesteryl ester content of #-VLDL. In addition, the lower cholesteryl ester content may be part of the explanation why the intermediate-expressing line 2 mice do not demonstrate f,-VLDL. Also, the total cholesterol/triglyceride ratio in line 2 mice is not different from that in nontransgenic mice and this may be a factor in determining electrophoretic mobility ofthe lipoprotein. To test the hypothesis that CETP plays a major role in the type III HLP response, we have crossed transgenic mice expressing high levels of cynomolgus monkey CETP (28) with either the high-expressing line 1 apo E(Arg-1 12, Cys-142) mice or the intermediate-expressing line 2 mice. In the former case, we expect that mice expressing both transgenes will have f3-VLDL with cholesteryl ester content more like that of human f3-VLDL. In the latter case, the addition of plasma CETP activity may be sufficient to yield the type III HLP phenotype in line 2 mice expressing intermediate levels of apo E(Arg-1 12, Cys-142) levels that are close to those in the human subjects with this variant (6) .
The impaired catabolism of transgenic mouse f3-VLDL was demonstrated by plasma turnover studies and is probably the mechanism accounting for accumulation of these lipoproteins in mouse plasma, just as it is the major mechanism for f3-VLDL accumulation in humans with type III HLP (1). These results further implicate the receptor binding-defective apo E(Arg-1 12, Cys-142) as the causal agent. Although plasma level differences preclude definitive comparisons, it is noteworthy that transgenic mice overexpressing either rat apo E (6-17 mg/dl; reference 11) or normal human apo E (25-35 mg/dl) (deSilva, H., J. Wang, S. Lauer, K. Weisgraber, R. Mahley, and J. Taylor, manuscript submitted for publication) do not demonstrate either hyperlipidemia or #l-VLDL. Instead, VLDL levels in those mice are reduced and apo B-containing lipoproteins are cleared more rapidly than nontransgenic VLDL (12, 29) .
The catabolism of the transgenic mouse (l-VLDL will be influenced by both the normal mouse apo E complement and the presence of apo C's, which are known to modulate apo E activity on f3-VLDL (30, 31 ) . Although we have not yet developed a plasma immunoassay to accurately measure endogenous mouse apo E, immunoblot comparisons with nontransgenic mice suggest that mouse apo E plasma levels are actually increased in the line 1 transgenic mice, and overall are probably at about the same ratio to human apo E that occurs in the #-VLDL fraction. This situation would suggest that mouse apo E is accumulating in plasma as a result of delayed clearance of the f3-VLDL particles on which it resides. AlthoVgh quantitative comparisons of apo C content have not been made, it appears that no major changes in apo C content result from the overexpression of the human apo E variant. Thus, the human apo E(Arg-1 12, Cys-142) apparently adds to the protein content of the d < 1.006 g/ml lipoproteins without displacing the apo C's.
In human type III HLP, plasma cholesterol and triglycerides are usually about equally elevated and the VLDL-cholesterol/plasma triglyceride ratio is typically > 0.3 (1), but the apo E(Arg-112, Cys-142) transgenic mice have plasma triglycerides two-to fivefold higher than cholesterol, and thus the diagnostic ratio of> 0.3 is not achievable. One possible explanation is that the transgenic mice are not strictly fasted overnight, but rather are sampled during the light cycle when they are not eating. However, although this may contribute to the variability among animals, it is unlikely to account forthe totality of the higher levels. Another possible explanation for the high triglycerides is that there could be a lipolytic processing defect of the transgenic fl-VLDL. Supporting this possibility is the finding that apo E(Arg-l 12, Cys-142) has reduced affinity for heparin (8) , which could be important in the lipolytic processing of triglyceride-rich lipoproteins. The possible lipolytic processing defect is also a testable hypothesis that we will investigate in these transgenic mice, but it will require comparisons with mice expressing other variants of apo E that would not be expected to have such a defect.
The null apo E mice recently reported by Zhang et al. ( 13) and Plump et al. ( 14) are similar to apo E-deficient humans in that they have hypercholesterolemia but only mildly elevated triglycerides and are prone to development of atherosclerosis.
Apo E-deficient humans have fl-VLDL, but it is not clear whether the null apo E mice have a comparable lipoprotein species ( 13 ) . Null apo E mice have both similarities and differences compared with the transgenic mice reported here that express dysfunctional apo E. The major similarity is that both types of mice develop spontaneous hyperlipidemia on normal chow diets. This result emphasizes the central role that apo E plays in lipoprotein metabolism. The major differences between the null apo E mice and transgenic mice expressing dysfunctional apo E are: null apo E mice have a more severe hypercholesterolemia but much less severe hypertriglyceridemia, null apo E mice have considerably more remnant-sized lipoproteins, and the apo B-containing lipoproteins of null apo E mice have a very different lipid and protein composition (e.g., presence of apo A-I and apo A-IV; apo B48/apo BlOO ratio > 20:1; see reference 13) . Investigations into the reasons for these differences may provide further insights into the role of apo E in lipoprotein metabolism. Transgenic mice expressing apo E(Arg-l 12, Cys-142) and other dysfunctional variants of apo E can be expected to be useful animal models for a variety of studies on type III HLP.
